文献速递其他结缔组织病血管炎

DNASE1L3 rs35677470变异增加系统性硬化症患者肺动脉高压易感性与死亡风险

Pulmonary arterial hypertension susceptibility and mortality among patients with systemic sclerosis with the DNASE1L3 rs35677470 (Arg206Cys) variant.
PubMed 文献 · Ann Rheum Dis · 2026-06-05

本研究在三个系统性硬化症(SSc)队列中分析DNASE1L3 R206C变异与死亡及肺部结局的关联。死亡分析纳入2366例患者,校正年龄和性别后该变异与死亡风险显著增加相关(HR 1.16, 95%CI 1.02-1.32);毛细血管前肺动脉高压分析纳入1170例患者,校正年龄、性别和ILD后该变异与毛细血管前肺动脉高压风险显著增加相关(HR 1.69, 95%CI 1.31-2.19)。结论提示DNASE1L3功能丧失与SSc患者肺动脉高压易感性相关。

要点

  • DNASE1L3 R206C变异与SSc患者死亡风险增加相关(HR 1.16)。
  • 该变异与毛细血管前肺动脉高压风险增加相关(HR 1.69)。
  • 多数毛细血管前肺动脉高压患者无ILD,提示WHO第1组肺动脉高压。

核心结论

  • DNASE1L3 R206C变异与SSc患者死亡风险及毛细血管前肺动脉高压风险增加显著相关。

研究设计与样本

  • 在UTHealth Houston、Royal Free Hospital和Johns Hopkins University三个队列中 ascertain 死亡、肺动脉高压和间质性肺病。
  • 死亡分析纳入2366例患者,其中46.6%已死亡;毛细血管前肺动脉高压分析纳入1170例患者,其中20.3%有毛细血管前肺动脉高压。
  • 使用Cox比例风险模型估计死亡风险和自SSc发病起毛细血管前肺动脉高压的时间-事件风险,并进行Meta分析生成总体风险估计。

主要发现

  • 校正SSc发病年龄和性别后,DNASE1L3 R206C与死亡风险显著增加相关(HR 1.16, 95%CI 1.02-1.32)。
  • 校正SSc发病年龄、性别和ILD后,DNASE1L3 R206C与毛细血管前肺动脉高压风险显著增加相关(HR 1.69, 95%CI 1.31-2.19)。
  • 多数毛细血管前肺动脉高压患者无ILD,提示为WHO第1组肺动脉高压(PAH)。

临床怎么用

  • 对携带DNASE1L3 R206C变异的SSc患者应加强死亡风险评估和肺动脉高压监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: A loss-of-function variant in deoxyribonuclease 1-like 3 (DNASE1L3), encoding Arg to Cys substitution at amino acid 206 (R206C), was previously identified as a heritable susceptibility factor for systemic sclerosis (SSc). We analysed mortality and pulmonary outcomes in patients with SSc with or without the DNASE1L3 R206C variant. METHODS: Mortality, pulmonary hypertension (PH), and interstitial lung disease (ILD) were ascertained in the UTHealth Houston, Royal Free Hospital, and Johns Hopkins University cohorts. Mortality risk and precapillary PH time-to-event from SSc onset were estimated using Cox proportional hazards models. Meta-analyses were performed to generate overall risk estimates. RESULTS: In the mortality analysis (n = 2366 patients, 46.6% of whom were deceased), after adjustment for age of SSc onset and sex, DNASE1L3 R206C was associated with significantly greater mortality (hazard ratio [HR]: 1.16, 95% CI: 1.02-1.32). In the precapillary PH analysis (n = 1170 patients, 20.3% of whom had precapillary PH), after adjustment for age of SSc onset, sex, and the presence of ILD, DNASE1L3 R206C was associated with significantly greater precapillary PH risk (HR: 1.69, 95% CI: 1.31-2.19). The majority of patients with precapillary PH did not have ILD, indicating that they had WHO Group I, ie pulmonary arterial hypertension (PAH). CONCLUSIONS: We report a previously unknown impact of DNASE1L3 polymorphism on PAH susceptibility in SSc. The association between loss-of-function of an immunoregulatory gene (DNASE1L3) and PAH susceptibility supports further exploration of downstream sequelae of DNASE1L3 dysfunction in SSc pathogenesis and the mechanisms underlying the well-recognised but poorly understood susceptibility of patients with SSc to PAH.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Skaug B, Rodolfi S, Denton CP, et al. Pulmonary arterial hypertension susceptibility and mortality among patients with systemic sclerosis with the DNASE1L3 rs35677470 (Arg206Cys) variant. Ann Rheum Dis. 2026. PMID: 42248770. doi:10.1016/j.ard.2026.05.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。